Últimas noticias sobre Aditxt (NASDAQ:ADTX) Bolsa

Aditxt

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.

Aditxt Inc

"In Q3 2024, we expect WiSA to deliver over 200% sequential revenue growth, driven by both WiSA HT and our new WiSA E IP being in production with a multi-national licensee," said Brett Moyer, CEO of WiSA Technologies. "This specific licensee, which is one of the five current WiSA E licensees signed to date, has integrated our WiSA E software into their source device and our WiSA E module in their speakers. Activation of the WiSA E transmit functionality triggers royalty payments back and generates additional revenue from the sale of WiSA E-enabled receiver modules using a Realtek Wi-Fi chip. We expect to build momentum with continued shipments to this customer with additional deployments anticipated in 2025."

News

Guidance

WISA

WiSA Sees Q3 2024 Revenue $1M-$1.2M Vs $300K QoQ

WIIM

ASE Tech Holding shares are trading higher after UBS upgraded the stock from Neutral to Buy.

RBC Capital analyst Gregory Renza maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and raises the price target from $30 to $34.

Price Target

Analyst Ratings

EXEL

RBC Capital Maintains Outperform on Exelixis, Raises Price Target to $34

New AI-Ready Platform, AI-Powered Bot Protection, And Expanded DDoS Protection Aim To Lower Cybersecurity Risks And Simplify IT Infrastructure

Biotech

General

PHIO

A10 Networks Unveils Blueprint To Secure AI Applications And Enhance Cyber Resilience With Integrated Solutions

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Hold and raises the price target from $26 to $30.

Stifel Maintains Hold on Exelixis, Raises Price Target to $30

Phio Pharmaceuticals To Present Data On INSTAYL Compound PH-894 At ASGCT's 2024 Cancer Conference; PH-894 Shows Potent Silencing Of BRD4 In NK Cells, Enhances NK Cell Proliferation And Cytotoxicity

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Roth MKM analyst Scott Stember reinstates Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Neutral and announces $40 price target.

Initiation

Roth MKM Reinstates Neutral on Advance Auto Parts, Announces $40 Price Target

Laboratory Corporation Of America Holdings

NOWDiagnostics Partners With Labcorp To Expand Access To First FDA-Authorized OTC Syphilis Test In The U.S.; First To Know Syphilis Test To Be Available In Clinical And Hospital Settings By Late 2024, With Direct Patient Access Via Labcorp OnDemand In 2025

VS: 489% &#x7C; <a href="https://www.benzinga.com//node/41354474">Versus Systems shares are trading higher after the company announced a $2.5 million investment and licensing agreement with ASPIS.</a>
&nbsp;
NVAX: -32% &#x7C; <a href="https://www.benzinga.com//node/41355032">Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</a>
&nbsp;
BDRX: 245% &#x7C; <a href="https://www.benzinga.com//node/41354484">Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.</a>

Movers

Trading Ideas

BDRX

NVAX

Market-Moving News for October 16th

Roth MKM analyst Scott Stember reinstates AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and announces $3634 price target.

Roth MKM Reinstates Buy on AutoZone, Announces $3634 Price Target

Alaska Airlines Enhances Mileage Plan For 2025 With New Perks, Faster Elite Status Earning, And Expanded Options For Earning And Redeeming Miles; Single Loyalty Program Coming As Alaska And Hawaiian Airlines Merge

ULTA

Ulta Beauty shares are trading lower after the company provided long-term business strategy plans and reaffirmed its F24 guidance.

A high-stakes power struggle has erupted between Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and activist investor Starboard Value, with Wall Street&#8217;s dealmaker, Alan Schwartz, and his firm, Guggenheim Partners, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41199793/amid-pfizers-struggles-with-declining-demand-for-covid-19-treatments-activist-investor-starboard" rel="noreferrer noopener">caught in the crossfire</a>.
The activist investor had built a $1 billion&nbsp;stake&nbsp;in the U.S. drug maker. The tension peaked when Pfizer&#8217;s former CEO Ian Read and former CFO Frank D&#8217;Amelio, who initially supported Starboard&#8217;s campaign against Pfizer&#8217;s current CEO Albert Bourla, unexpectedly <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb" rel="noreferrer noopener">reversed their stance</a>.
Read and D&#8217;Amelio issued a statement expressing full support for Bourla and the board, though this sudden shift in allegiance left insiders puzzled.
Even more surprising was that the statement was released through Guggenheim, a firm that has enjoyed a close relationship with Pfizer and has earned approximately $172 million in advisory fees since 2011, most recently $48 million from the&nbsp;Seagen deal.
Speculation surrounds the reversal, with Jeff Smith, CEO of Starboard, claiming Pfizer pressured the ex-executives with potential legal consequences <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41274121/whats-going-on-with-pfizer-stock-on-thursday" rel="noreferrer noopener">and bonus clawbacks</a>.
Despite not playing an official role in the Starboard-Pfizer dispute, Guggenheim finds itself entangled in one of Wall Street&#8217;s most contentious activist campaigns.
The Financial Times <a target="_blank" href="https://www.ft.com/content/1546d1e6-3bd6-43d8-b17a-919308096ef0" rel="noreferrer noopener">notes</a> that Pfizer has since turned to rival boutique firm PJT Partners to lead its defense, distancing itself from its long-time advisor in this high-profile clash.
Starboard&#8217;s frustration stems from Pfizer&#8217;s declining performance since its COVID-19 vaccine windfall. The company has faced criticism for a series of costly acquisitions, including its $43 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">purchase of </a><a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">Seagen</a>.
The FT report highlights that Starboard <a target="_blank" href="https://www.ft.com/content/0f3e13bd-ba02-47a6-9261-1e49d19d6528" rel="noreferrer noopener">argues</a> that these moves, along with poor capital allocation, have contributed to Pfizer&#8217;s stock dropping over 50% from its pandemic peak. The activist investor will likely push for significant changes, possibly including a leadership overhaul or further divestitures.
With Pfizer&#8217;s stagnant revenue growth and limited options for quick fixes, Starboard&#8217;s path to reshaping the company remains uncertain.
Pfizer has already implemented cost-cutting measures and sold off divisions, leaving few levers for change.
Price Action: PFE stock is up 0.31% at $29.53 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" target="_blank" rel="noreferrer noopener">FDA Approves Pfizer&#8217;s Second Hemophilia Drug Within Six Months</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle

Roth MKM analyst Scott Stember reinstates O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Buy and announces $1337 price target.

ORLY

Roth MKM Reinstates Buy on O'Reilly Automotive, Announces $1337 Price Target

TD Cowen analyst Krish Sankar maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and lowers the price target from $23 to $20.

SVCO

TD Cowen Maintains Buy on Silvaco Group, Lowers Price Target to $20

U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading higher on Wednesday.</a>
The company reported <a target="_blank" href="https://s203.q4cdn.com/711684571/files/doc_financials/2024/q3/Press-Release-3Q24.pdf" rel="noreferrer noopener">third-quarter</a> adjusted earnings per share of $1.03, beating the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41353142/u-s-bancorp-reports-third-quarter-2024-results" rel="noreferrer noopener">consensus estimate of 99 cents.</a>
Quarterly revenues of $6.864 billion missed the analyst consensus estimate of $6.895 billion.
The third quarter included $119 million of net losses on investment securities sales ($89 million net-of-tax), which was largely offset by lower income tax expenses, which reflected certain tax settlements.
&#8220;Our expense levels decreased year-over-year which supported modest positive operating leverage, excluding net securities losses and prior year notable items,&#8221; said Andy Cecere, Chairman and CEO, U.S. Bancorp.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist" rel="noreferrer noopener">Banks Gear Up For Earnings Season: 15 Top Stock Picks Including Citigroup, Morgan Stanley, And Truist</a>
Net interest income fell 2.4% to $4.135 billion in the quarter under review, due to the impact of higher interest rates on deposit mix and pricing. Third quarter noninterest income of $2.698 billion, down 2.4% year over year.
The provision for credit losses increased by $42 million (8.2%) compared with the third quarter of 2023, largely due to higher losses on credit card, commercial, and commercial real estate loans.
&#8220;Credit quality results were in line with expectations, and we continue to increase our capital position, ending the quarter with a CET1 capital ratio of 10.5%,&#8221; Cecere added. The CET1 capital ratio of 10.5% on September 30 was up from 10.3% on June 30.
The average total deposits for the third quarter were $3.5 billion, which was 0.7% lower year over year.
Price Action: USB shares are trading higher by 1.91% to $47.90 premarket at last check Wednesday.
Photo by JHVEPhoto via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41249837/s-p-500-earnings-season-kicks-off-why-analysts-call-this-quarter-a-stock-pickers-paradise" target="_blank" rel="noreferrer noopener">S&amp;P 500 Earnings Season Kicks Off: Why Analysts Call This Quarter ‘A Stock Picker's Paradise'</a></li>
</ul>

Earnings

Equities

Markets

U.S. Bancorp Q3 Earnings: EPS Beat, Revenue Miss, Rising Credit Loss Provisions & More

<a href="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture" title="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture">https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture</a>

'BlackRock in Talks With Ambani for India Private Credit Venture' - Bloomberg

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) are surging, with the former benefitting from social media chatter about Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41220500/elon-musk-says-potential-doge-department-under-a-trump-administration-will-be-a-garbage-co">heading a &#8220;D.O.G.E&#8221; department. </a>
What Happened: Dogecoin, Shiba Inu and Dogecoin-themed cryptocurrencies have performed exceptionally well over the past 24 hours:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Market cap</td>
<td>  24-hour trend</td>
<td>7-day trend</td>
</tr>
<tr>
<td>Dogecoin </td>
<td>$0.1256</td>
<td>$18.386B</td>
<td> +11.2%</td>
<td>+15.1%</td>
</tr>
<tr>
<td>Shiba Inu </td>
<td>$0.00001875</td>
<td>$11.04B</td>
<td> +5.2%</td>
<td>+7.2%</td>
</tr>
<tr>
<td>Department Of Government Efficiency (D.O.G.E)</td>
<td>$0.026</td>
<td>$25.68M</td>
<td>+122.4%</td>
<td>+152.4%</td>
</tr>
</tbody>
</table>
</figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313977/dogecoins-on-chain-data-chart-patterns-flash-bullish-signals-this-top-analyst-thinks-its-a">Dogecoin&#8217;s On-Chain Data, Chart Patterns Flash Bullish Signals: This Top Analyst Thinks It&#8217;s A &#8216;Buy&#8217;</a>
Trader Notes: Crypto analysts are speculating on the potential impact of <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313912/harris-or-trump-bitcoin-to-be-in-win-win-position-irrespective-of-who-wins-the-white-house">a Trump victory</a> in the upcoming U.S. presidential election on certain cryptocurrencies, particularly those associated with the &#8220;DOGE&#8221; narrative.
Andrew Kang <a href="https://x.com/Rewkang/status/1846231275847454786">suggests</a> that owning Dogecoin and other meme coins could be &#8220;one of the most interesting ways to express a &#8216;Trump Victory&#8217; trade.&#8221; He points to the increased likelihood of a <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39334602/arthur-hayes-raoul-pal-predict-dogecoin-etf-if-people-wait-in-line-for-luxury-brands-they-">Dogecoin ETF</a> and the potential creation of a<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40780511/dogecoin-surges-8-as-elon-musk-jokes-doge-will-be-the-official-mascot-of-department-of-gov"> Department of Government Efficiency (DOGE)</a> under a Trump administration, which could keep the cryptocurrency in the headlines.
Supporting this view, analyst Unipcs <a href="https://x.com/theunipcs/status/1846474366684438605">highlights</a> the recent performance of DOGE-related assets, stating, &#8220;it&#8217;s hard not to be bullish on both doges if you really think Trump is going to win.&#8221; 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Statistics: IntoTheBlock data shows Dogecoin's large transaction volume increasing by 4.6% and daily active addresses falling by 1.5%. Transactions greater than $100,000 are up from&nbsp; 317 to 394 in a single day.
Shiba Inu's large transaction volume is down by 24.5% and daily active addresses are up by 17.2%. Shiba Inu has burned around 3 million SHIB coins from its ecosystem over the past 24 hours.
Community News: The official Dogecoin account picked up on a Shiba Inu-themed easter egg in Tesla&#8217;s Robotaxi presentation:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hey <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> is that a Shiba Inur taxi? <a href="https://t.co/ihfktgc4ds">pic.twitter.com/ihfktgc4ds</a>
&mdash; Dogecoin (@dogecoin) <a href="https://twitter.com/dogecoin/status/1844591727656448375?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Dogecoin-themed account Doge Designer <a href="https://x.com/cb_doge/status/1844595234316943841">noted</a> the same, wondering whether Musk would really allow purchases with Dogecoin in the future.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41312634/dogecoin-killer-shiba-inu-incinerates-277m-coins-in-1-transaction-watch-these-levels-for-a">&#8216;Dogecoin Killer&#8217; Shiba Inu Incinerates 277M Coins In 1 Transaction: Watch These Levels For A Bullish Rally</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Dogecoin Rockets Up 10%, Shiba Inu Spikes 5%: What Is Going On?

Keybanc analyst Matthew Gillmor maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $675 to $650.

Keybanc Maintains Overweight on UnitedHealth Group, Lowers Price Target to $650

Aditxt signs second amendment to arrangement agreement with Appili Therapeutics

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) stock is rising higher on Wednesday after the company notified investors of an <a href="https://finance.yahoo.com/news/aditxt-subsidiary-pearsanta-seeks-clinical-121500225.html">update on a clinical trial</a> conducted by its subsidiary Pearsanta.



According to a press release from Aditxt, Pearsanta has submitted a Clinical Trial Translational Endpoints Research Award proposal to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense.



Aditxt notes that this proposal seeks to validate a novel assay based on Pearsanta&rsquo;s Mitomic Technology. The goal would be to use this for the early detection of ovarian cancer.



Chris Mitton, president of Pearsanta, said the following about this update.




&ldquo;Submitting this proposal to the CDMRP is another step in our mission to revolutionize early cancer detection. Our proprietary Mitomic Technology aims to provide a reliable, non-invasive, and effective blood test that can lead to earlier detection, more effective treatments, and, ultimately, save lives.&rdquo;




<h2>ADTX Stock Movement Today</h2>



With this news comes heavy trading of ADTX stock today. That has more than 97 million shares changing hands as of this writing. This is a massive increase compared to its daily average of about 615,000 shares.



ADTX stock is up 48.8% as of Wednesday afternoon.



There are more stock market stories ready to go below!



We have all of the hottest stock market news available on Wednesday! That includes what&rsquo;s going on with shares of Novo Nordisk&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) stock, Sunrun&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/run-stock-quote/">RUN</a>) stock and political trades today. All of that news is ready to go at the links below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/nvo-stock-alert-why-is-novo-nordisk-down-8-today/">NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/run-stock-alert-surprise-why-sunrun-stock-is-up-17-today/">RUN Stock Alert: Surprise! Why Sunrun Stock Is Up 17% Today.</a></li>



<li><a href="https://investorplace.com/2024/08/the-top-stocks-politicians-are-buying-and-selling-this-week/">The Top Stocks Politicians Are Buying and Selling This Week</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/biotech-news-why-is-aditxt-adtx-stock-up-49-today/">Biotech News: Why Is Aditxt (ADTX) Stock Up 49% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Biotech News: Why Is Aditxt (ADTX) Stock Up 49% Today?

Aditxt sells 1.13M shares at $1.06 in registered direct offering

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!



Moving stocks are new patents, insider buying, a company name change and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>PS International Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/psig-stock-quote/">PSIG</a>) stock is rocketing more than 81% alongside heavy pre-market trading.</li>



<li>Ainos (NASDAQ:<a href="https://investorplace.com/stock-quotes/aimd-stock-quote/">AIMD</a>) shares are soaring over 47% after <a href="https://www.nasdaq.com/press-release/ainos-secures-exclusive-multi-regions-invention-patent-licenses-strategic-partner">securing new patent licenses</a>.</li>



<li>LogicMark (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgmk-stock-quote/">LGMK</a>) stock is surging more than 38% alongside details of an upcoming <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318511278&amp;type=PDF&amp;symbol=LGMK&amp;cdn=5653ec5b97d2382396937934a20579e2&amp;companyName=LogicMark+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-08-09">special shareholder meeting</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining over 25% despite a lack of news this morning.</li>



<li>Genius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/gns-stock-quote/">GNS</a>) stock is increasing more than 19% <a href="https://www.nasdaq.com/press-release/genius-group-founder-ceo-roger-james-hamilton-purchase-10-million-shares-2024-08-09">on insider buying</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) shares are rising over 19% on <a href="https://www.nasdaq.com/press-release/fsd-pharma-announces-share-consolidation-and-name-change-2024-08-09">share consolidation and name change plans</a>.</li>



<li>ProMIS Neurosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmn-stock-quote/">PMN</a>) stock is climbing more than 17% this morning.</li>



<li>ConnectM Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntm-stock-quote/">CNTM</a>) shares are heading over 17% higher without any clear news today.</li>



<li>BioVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/bivi-stock-quote/">BIVI</a>) stock is jumping more than 15% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 14% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) stock is plummeting more than 27% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318511870&amp;type=PDF&amp;symbol=AILE&amp;cdn=8f0ca76b44522478ea48d6b3e52f5445&amp;companyName=iLearningEngines+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-08-09">pricing a public offering</a>.</li>



<li>Meta Materials (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmat-stock-quote/">MMAT</a>) shares are diving over 17% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318508874&amp;type=PDF&amp;symbol=MMAT&amp;cdn=747b3fffafae953c1fe1c54f998009fd&amp;companyName=Meta+Materials+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-09">filing for bankruptcy</a>.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) stock is tumbling more than 15% after <a href="https://finance.yahoo.com/news/sonoma-pharmaceuticals-first-quarter-2025-120225512.html">missing fiscal Q1 2025 earnings estimates</a>.</li>



<li>Tenon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnon-stock-quote/">TNON</a>) shares are taking an over 15% beating despite any clear news this morning.</li>



<li>Humacyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/huma-stock-quote/">HUMA</a>) stock is sliding more than 13% <a href="https://www.stocktitan.net/news/HUMA/humacyte-announces-fda-communication-of-additional-time-required-to-5oxy7ry3qlgj.html">on an update</a> from the Food and Drug Administration (FDA).</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are falling over 12% on a <a href="https://www.nasdaq.com/press-release/aditxt-announces-12-million-registered-direct-offering-priced-market-under-nasdaq">registered direct offering</a>.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) stock is dropping close to 12% on a <a href="https://finance.yahoo.com/news/caremax-inc-cmax-reports-q2-224503059.html">Q2 loss and revenue miss</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) shares are decreasing more than 10% <a href="https://www.nasdaq.com/press-release/big-tree-cloud-holdings-limited-receives-nasdaq-notification-regarding-minimum-market">with a delisting notice</a>.</li>



<li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is slipping over 10% this morning.</li>



<li>Bright Minds Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/drug-stock-quote/">DRUG</a>) shares close out our pre-market stock movers down more than 10% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-aug-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) just reported results for the second quarter of 2024.<ul><li>Aditxt reported earnings per share of -$4.19.</li><li>The company reported revenue of $44,276.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/adtx-stock-earnings-aditxt-for-q2-of-2024/">ADTX Stock Earnings: Aditxt Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ADTX Stock Earnings: Aditxt Reported Results for Q2 2024

Aditxt files to sell $150M of common stock

Aditxt and Evofem amend merger agreement

Aditxt, Inc. ( ($ADTX) ) has issued an update. Aditxt, Inc. is geared up to present its operational and performance strategies through Presentation...

Aditxt, Inc. Outlines Growth Strategies at Global Investment Conference

Aditx Therapeutics announces 1-for-40 reverse stock split for Nasdaq compliance

The latest update is out from Aditxt, Inc. ( ($ADTX) ). Amro Albanna, CEO of Aditxt, Inc., recently held an informative stakeholder update and Q&A ...

Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy

ADTX

AILE

AIMD

APLIF

AZTR

BIVI

CMAX

CNTM

DRUG

EVFM

HUGE

HUMA

LGMK

MMAT

PRTG

PSIG

SNOA

TNON

VSME

Press Releases

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Comments

Aditxt

Noticias

Últimas noticias sobre Aditxt (NASDAQ:ADTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL